One of the more accepted concepts in our understanding of the biology of early
Trypanosoma cruzi–host cell interactions is that the mammalian-infective trypomastigote …

Pathophysiology of Chagas' disease is not completely defined, although innate and
adaptative immune responses are crucial. In acute infection some parasite antigens can …

Chagas' disease, caused by the hemoflagellate protozoan Trypanosoma cruzi, affects
millions of people in South and Central America. Chronic chagasic cardiomyopathy, the …

Trypanosoma cruzi parasites are the causative agents of Chagas disease, a leading
infectious form of heart failure whose pathogenesis is still not fully characterized. In this …

More than 10 million people are thought to be infected with Trypanosoma cruzi, primarily in
the Americas. The clinical manifestations of Chagas' disease (CD) are variable, but most …

Heart tissue inflammation, progressive fibrosis and electrocardiographic alterations occur in
approximately 30% of patients infected by Trypanosoma cruzi, 10-30 years after infection …

Trypanosoma cruzi, the etiological agent of Chagas' disease, affects 8 million people
predominantly living in socioeconomic underdeveloped areas. T. cruzi trypomastigotes (Ty) …

Chagas disease, which was once thought to be confined to endemic regions of Latin
America, has now gone global becoming a new worldwide challenge. For more than a …

Invasion of mammalian cells by T. cruzi trypomastigotes is a multi-step and complex process
involving several adhesion molecules, signaling events and proteolytic activities. From the …

During infectious diseases, neuroendocrine and immune networks act in concert, facilitating
host response. It is known that infections cause profound immune changes, but the impact …